Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jul 15, 2025; 17(7): 106723
Published online Jul 15, 2025. doi: 10.4251/wjgo.v17.i7.106723
Published online Jul 15, 2025. doi: 10.4251/wjgo.v17.i7.106723
Adoptive cell therapy in colorectal cancer: Advances in chimeric antigen receptor T cells
Meng-Yan Chen, Chen Wang, Yu-Gang Wang, Min Shi, Department of Gastroenterology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China
Co-first authors: Meng-Yan Chen and Chen Wang.
Co-corresponding authors: Yu-Gang Wang and Min Shi.
Author contributions: Shi M and Wang YG conceptualized the theme and structure of this review; Chen MY was the primary contributor to the manuscript writing; Wang C provided guidance and revised the initial draft; All authors have read and approved the final manuscript.
Supported by the Natural Science Foundation of the Science and Technology Commission of Shanghai Municipality, China, No. 23ZR1458300; Key Discipline Project of Shanghai Municipal Health System, China, No. 2024ZDXK0004; Doctoral Innovation Talent Base Project for Diagnosis and Treatment of Chronic Liver Diseases, China, No. RCJD2021B02; and Pujiang Project of Shanghai Magnolia Talent Plan, China, No. 24PJD098.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Min Shi, MD, Chief Physician, Department of Gastroenterology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, No. 1111 Xianxia Road, Changning District, Shanghai 200336, China. sm1790@shtrhospital.com
Received: March 6, 2025
Revised: April 7, 2025
Accepted: May 29, 2025
Published online: July 15, 2025
Processing time: 131 Days and 4.3 Hours
Revised: April 7, 2025
Accepted: May 29, 2025
Published online: July 15, 2025
Processing time: 131 Days and 4.3 Hours
Core Tip
Core Tip: This review discusses adoptive cell therapy approaches for colorectal cancer (CRC), emphasizing chimeric antigen receptor (CAR) T cell therapy. Despite its success in hematological malignancies, CAR-T therapy faces challenges in solid tumors like CRC, including antigen heterogeneity, tumor microenvironment immunosuppression, and on-target off-tumor toxicity. In this review, we explore combinatorial strategies, such as immune checkpoint inhibitors and CRISPR/Cas9 gene editing, to overcome these challenges and enhance CAR-T cell specificity, resistance to immunosuppressive signals, and in vivo functionality.